

Asthma Over the Age of 65: All's Well That Ends Well



Alan P. Baptist, MD, MPH^a, and Paula J. Busse, MD^b *Ann Arbor, Mich; and New York, NY*

INFORMATION FOR CATEGORY 1 CME CREDIT

Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.

Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the *JACI: In Practice* Web site: www.jaci-inpractice.org/. The accompanying tests may only be submitted online at www.jaci-inpractice.org/. Fax or other copies will not be accepted.

Date of Original Release: May 1, 2018. Credit may be obtained for these courses until April 30, 2019.

Copyright Statement: Copyright © 2018-2020. All rights reserved.

Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.

Target Audience: Physicians and researchers within the field of allergic disease.

Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for

1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

List of Design Committee Members: Alan P. Baptist, MD, MPH, and Paula J. Busse, MD (authors); Michael Schatz, MD, MS (editor)

Learning objectives:

1. To understand the epidemiology of older patients with asthma.
2. To recognize the pathophysiologic changes in the innate and immune system in older patients with asthma.
3. To understand the challenges of diagnosing and treating older patients with asthma.

Recognition of Commercial Support: This CME has not received external commercial support.

Disclosure of Relevant Financial Relationships with Commercial Interests: A. P. Baptist is employed by University of Michigan, Division of Allergy; and has received research grants from Shire (on the topic of Angioedema) and from Novartis (on the topic of Asthma), from the National Institutes of Health (1 R01 AG043401-01). P. J. Busse is employed by Mount Sinai School of Medicine. M. Schatz declares no relevant conflicts of interest.

Asthma in older adults (often classified as those 65 years or older) is relatively common, underdiagnosed, and suboptimally treated. It is an important health problem, as the population of the United States continues to age. Unfortunately, asthma morbidity and mortality rates are highest in this age group. Alterations in the innate and adaptive immune responses occur with aging, and contribute to pathophysiologic differences and subsequent treatment challenges. The symptoms of asthma may

differ from those in younger populations, and often include fatigue. There are unique factors that can complicate asthma management among older adults, including comorbidities, menopause, caregiver roles, and depression. Pharmacologic therapies are often not as effective as in younger populations, and may have greater side effects. Spirometry, peak flow measurements, and asthma education are typically underused, and may contribute to delays in diagnosis as well as worse outcomes. There are specific strategies that health care providers can take to improve the care of older adults with asthma. © 2018 American Academy of Allergy, Asthma & Immunology (*J Allergy Clin Immunol Pract* 2018;6:764-73)

Key words: Asthma; Older adults; Elderly; Spirometry; Immunosenescence; Depression; Menopause; Education; Asthma COPD overlap syndrome

INTRODUCTION

To many, there is the belief that asthma occurs in childhood and resolves over time. However, studies show that a significant number of people first develop asthma at a relatively older age, and that it can persist throughout the lifespan. Understanding asthma in older adults is critical to health care providers and researchers, as the number of those older than 65 years in the

^aDepartment of Medicine, Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich

^bIcahn School of Medicine at Mount Sinai, New York, NY

Conflicts of interest: A. P. Baptist is employed by the University of Michigan, Division of Allergy; and has received research grants from Shire (on the topic of Angioedema), Novartis (on the topic of Asthma), and the National Institutes of Health (grant no. 1 R01 AG043401-01). P. J. Busse is employed by Mount Sinai School of Medicine.

Received for publication October 24, 2017; revised January 29, 2018; accepted for publication February 3, 2018.

Corresponding author: Alan P. Baptist, MD, MPH, University of Michigan Department of Medicine, Division of Allergy and Clinical Immunology, 24 Frank Lloyd Wright Dr, Ste H-2100, Ann Arbor, MI 48106. E-mail: abaptist@med.umich.edu.

2213-2198

© 2018 American Academy of Allergy, Asthma & Immunology
<https://doi.org/10.1016/j.jaip.2018.02.007>

Abbreviations used

ACO- Asthma COPD overlap
CAM- Complementary and alternative medicine
COPD- Chronic obstructive pulmonary disease
HRT- Hormone replacement therapy
ICS- Inhaled corticosteroid
LOA- Late-onset asthma
OR- Odds ratio

United States is projected to increase to 85 million individuals by the year 2045, a 77% increase since 2015 (Figure 1).¹ In addition, by 2030, the percent of older adults will increase to 20% of the total population, and therefore those who manage adult asthma will likely have many patients older than 65 years. This review covers unique features of asthma in older adults, discusses challenges of diagnostic and management strategies, and highlights areas in which further research is needed to address knowledge gaps.

EPIDEMIOLOGY

Accurate data on the prevalence of asthma in older adults can be difficult to obtain. In part, this is because many asthma trials specifically exclude individuals older than 65 years. In addition, in the older adult with respiratory symptoms, often times those with a minimal, remote, or even nonexistent smoking history are misdiagnosed as having chronic obstructive pulmonary disease (COPD) rather than asthma,^{2,3} even though data suggest that approximately 20 pack-years are typically required to develop COPD.⁴ A 2015 Centers for Disease Control and Prevention survey found that among adults, the prevalence of asthma is highest in those aged 45 to 64 years, with 8.4% having a current diagnosis of asthma.⁵ This was the same prevalence as the overall rate for children aged 0 to 18 years. Therefore, asthma remains a common chronic disease across all ages.

Results of the Centers for Disease Control and Prevention Asthma Call Back Survey (~900,000 individuals) did find that the assumption of asthma typically beginning in childhood is often, but not always, true.⁶ Among all children, asthma incidence was 12.5 per 1000. However, new cases of asthma occurred frequently at any age. In adults older than 18 years, the greatest incidence rate was in those aged 55 to 64 years (4.6 per 1000). In those older than 65 years, the incidence rate was 3.1 per 1000. More recently, Baptist et al⁷ reported that among 180 patients older than 55 years with persistent asthma, 46% were diagnosed after the age of 40 years.⁷ Taken together, these data indicate that asthma is common in those older than 65 years, and that many cases begin later in life.

There appear to be clinical differences between those who develop asthma in childhood, adolescence, or young adulthood (termed “long-standing asthma”) and those who develop asthma after the age of 40 years (termed “late-onset asthma,” or LOA). Those with LOA are more likely to have frequent symptoms, less atopy, and a decreased response to standard inhaled corticosteroids and beta-agonists,^{8,9} though some authors have suggested that those with long-standing asthma may in fact have worsened outcomes.¹⁰ Recent cluster analyses of older adults have been published, and will help to clarify these issues as well as identify specific phenotypes that may respond preferentially to one treatment over another.^{7,11}

What does seem clear is that older adults have some of the highest asthma morbidity and mortality rates. For example, as shown in Figure 2, the mortality rate from asthma steadily increases with age.¹² In addition, studies of severe asthma have shown that older adults may have a more difficult-to-control phenotype than younger populations, with decreased responsiveness to standard medications.^{7,13,14} Of those presenting to the emergency department for asthma, adults 65 years or older have the highest rate who subsequently require hospitalization (~25% admission rate compared with 7.9% for all ages) and longest length of stay.¹⁵ It is important to note that asthma is frequently underdiagnosed, and therefore these numbers may be underestimations.

IMMUNOSENESCENCE

With increasing age, there are alterations in both the innate and adaptive immune responses, which likely impact the pathology, and consequently, the treatment, of asthma in older adults. Two distinct alterations of aging in the innate and adaptive immune responses have been described and can occur simultaneously. One, “immunosenescence,” is a “blunted” response after a pathogenic threat or tissue injury. However, despite an inability to proliferate, some senescent cells remain alive, functioning at an altered capacity. This results in the second process, “inflammaging,” an increased low-grade basal systemic inflammation (eg, IL-1 β , IL-6, and TNF- α) in the absence of an overt infection.¹⁶ The mechanisms of immunosenescence and inflammaging are the consequence of both “random” (eg, environmental exposures, accumulation of reactive oxygen species from metabolic activity, and mutagenesis) and “regulated” (eg, genetic) events.¹⁷

The possible impacts of immunosenescence and inflammaging on asthma are briefly outlined in Table I. Collectively, alterations in innate and adaptive cells likely have several clinical implications including decreasing the response to vaccinations and increasing rates of infections, which in turn may exacerbate asthma, or play a role in the inception of LOA.¹⁸ Furthermore, older patients with asthma may have altered airway and systemic inflammation (ie, higher neutrophils with increased IL-6, IL-8, C-reactive protein) resembling changes seen in a phenotype of severe asthma in younger patients, which is often less responsive to corticosteroid treatment.¹⁹⁻²¹

SYMPTOMS AND DIAGNOSIS

Many of the asthma symptoms common in younger patients (eg, intermittent chest tightness, nocturnal wheezing, and dyspnea) are present in older patients. However, there are important considerations. Older adults frequently note fatigue as a principal symptom, even in the absence of typical asthma manifestations.²² Dyspnea is commonly associated with other chronic disorders in older patients (eg, heart failure, other lung diseases, and anemia); therefore, asthma as the cause of these symptoms may be overlooked. Furthermore, some older patients may limit their activity to avoid becoming dyspneic, or attribute it to aging itself. Older adults may have a decreased perception of dyspnea even with significant airflow obstruction.^{23,24} As smoking can induce symptoms of wheeze, cough, and sputum production, asthma may be confused with COPD. Prominent gastroesophageal reflux disease may present with a chronic cough, hoarseness, and




FIGURE 1. Projected US population 65 years or older. Projections based on 2015 analysis of US Census data by Population Reference Bureau.

wheezing, and therefore needs to be considered in the differential diagnosis of asthma.²⁵

The same objective measures used to diagnose asthma in younger patients are used in older patients. However, similar to symptoms of asthma in this group, there are age-related factors that must be considered. First, the FEV₁/forced vital capacity ratio decreases with aging, and therefore, it is essential to use age-adjusted values.^{26,27} Second, with aging, bronchial hyper-responsiveness to methacholine increases²⁸⁻³⁰; therefore, provocation testing may be less accurate in this age group. Bronchoprovocation challenges may be contraindicated in some older patients with low baseline lung function or cardiac comorbidities. Third, spirometry involves effort-dependent maneuvers. More than 80% of older persons can achieve American Thoracic Society—acceptable results; however, it may be difficult for those who are frail.³¹⁻³⁷ Poor coordination and muscle weakness in some patients may produce inaccurate readings of peak expiratory flow.^{38,39} Unfortunately, objective measures of lung function such as spirometry and peak flow measurements are generally underused in older patients and contribute to the delay in diagnosis.³⁵

Other tests such as the carbon monoxide diffusing capacity of the lung may help distinguish between asthma and COPD. Chest computed tomography may demonstrate increased wall thickness, and increased air-trapping in older patients with asthma.⁴⁰ The use of exhaled nitric oxide in older patients is not completely established, and aging itself can increase exhaled nitric oxide.^{41,42} Some studies using exhaled nitric oxide as a marker for asthma diagnosis and a measure of control in older patients have shown it to be beneficial,⁴³⁻⁴⁷ whereas others have not.⁴⁸

UNIQUE FACTORS THAT CAN COMPLICATE ASTHMA MANAGEMENT AMONG OLDER ADULTS— AND STRATEGIES TO ADDRESS THEM

Comorbidities

In recent years, there has been a significant increase in the literature demonstrating that comorbidities significantly influence asthma management and control. A 2016 meta-analysis of 11 studies involving 460,000 patients found that patients with




FIGURE 2. Mortality rates for asthma among different age groups (young children, adolescents, young adults, and older/very old adults). Adapted from Kochanek et al.¹²

asthma were more likely to have cardiovascular disease (odds ratio [OR] = 1.9), obesity (OR = 1.51), gut or urinary comorbidities (OR = 1.62), and hypertension (OR = 1.91) compared with those without asthma ($P < .0001$ for all comparisons listed).⁴⁹ The National Health and Nutrition Examination Survey revealed that adult patients with asthma with comorbidities were more likely to have asthma symptoms, activity limitations, and emergency department visits for asthma compared with patients with asthma without comorbidities.⁵⁰ Data specifically looking at adults 65 years or older have confirmed that in this age group, comorbidities are directly related to asthma hospitalizations and emergency department visits.⁵¹ As people age, the number of medical conditions and medications to manage these conditions increase. Therefore, the negative impact of comorbidities and asthma management has a greater impact on older adults.

In older adults, comorbidities can impact asthma management in a number of ways. There can be interactions between conditions, similar symptom presentation of asthma and comorbidities, decreased adherence with multiple medications, and conflicting recommendations on care from numerous specialists.⁵² In a qualitative study, older adults with asthma and cardiac disease describe having been instructed by their physician to try medications for both conditions simultaneously and/or sequentially during episodes of dyspnea.²² In addition, in patients with multiple comorbidities, asthma may take a “back seat” during a primary care office visit, and be suboptimally addressed.

To improve the care of older adults with asthma, clinicians should identify, acknowledge, and address comorbidities where appropriate. A recent study by Tay et al⁵³ found that asthma outcomes improved when asthma specialists identified and subsequently treated or referred patients for specific comorbidities (eg, gastroesophageal reflux disease, sleep apnea, or obesity). In addition, emphasizing to a patient that suboptimal asthma control can make exercise and weight loss problematic may impress upon some the importance of regular asthma care. With

TABLE I. Impacts of immunosenescence and inflammaging on asthma

Immune response	Cell type	Age-associated changes
Innate	Neutrophils	• ↑ number of cells in BALF and neutrophil elastase in those without asthma¹²⁹ • ↑ number of cells in sputum of older vs younger patients with asthma^{19,21,130} • ↑ number of sputum neutrophil mediators in older patients with asthma (IL-8, MMP-9)^{19,21} • ↓ chemotaxis¹³¹ • ↓ secretion of neutrophil extracellular traps, which normally function to immobilize bacteria¹³² • ↓ phagocytosis^{133,134} • ↑ basal production of ROS and neutrophil elastase (damages local tissues)^{131,135,136} • ↓ production of ROS in response to bacterial infection^{135,137}
	Eosinophils	• ↓ degranulation of peripheral cells in response to IL-5 in older patients with asthma¹³⁸ • ↑ peripheral number of cells associated with development of BHR and aging in men (Normative Aging Study)¹³⁹
	Dendritic cells	• ↑ IL-6 and TNF-α expression and ↓ IFN-γ^{140,141} • ↓ phagocytosis¹⁴² • ↓ Toll-like receptor function¹⁴³ • ↓ migration¹⁴⁴
	Macrophages	• ↓ phagocytosis^{134,145} • ↓ TLR expression¹⁴⁶ • ↑ TNF-α, IL-8 expression¹⁴⁷
	Epithelial cells	• ↓ ciliary beat frequency^{148,149} • ↓ barrier function due to loss of tight cellular junctions¹⁵⁰
Adaptive	B-Lymphocytes	• ↓ ability to produce specific, long-lasting, and diverse antibodies to antigens (eg, vaccination and infection)¹⁵¹ • ↓ naive cells produced by the bone marrow¹⁵² • ↓ Total IgE^{153,154} • ↓ Antigen-specific IgE (however, antigen sensitization in older patients with asthma not uncommon, but its effect on asthma not clear)^{155,156}
	T-Lymphocytes	• ↓ naive T cells as thymus involutes¹⁵⁷ • ↑ number of circulating T cells due to increase in the number of memory T cells¹⁵⁸ • ↓ expression of CD154 (CD40L), decreasing B-cell activation, and antibody class switching^{159,160} • ↑ survival of memory CD8+ cells, possibly due to chronic cytomegalovirus stimulation^{161,162} (inverted CD4:CD8 ratio in older adults with asthma, associated with decreased asthma control [unpublished data, P. J. Busse, MD, 2017])
	T _H 17 cells	• ↑ number with aging¹⁶³ • ↑ number in BALF of LOA animal model^{21,164}

BALF, Bronchoalveolar fluid lavage; BHR, bronchial hyperresponsiveness; LOA, late-onset asthma; MMP-9, matrix metalloproteinase 9; ROS, reactive oxygen species.

improved control, it may be possible for the older adult to reduce the burden of other conditions such as cardiac disease, diabetes, and obesity.

Treatment of comorbid allergic rhinitis with nasal corticosteroids is a relatively safe approach in older adults, and may be an option to improve asthma control without stepping up controller therapy.⁵⁴ Specific immunotherapy improves allergic rhinitis in older patients, but risks including anaphylaxis and the use of epinephrine in patients with significant cardiac disease must be considered.⁵⁵ Sublingual immunotherapy has a lower incidence of serious adverse effects and may be an attractive alternative in older adults, though currently most formulations are approved only to the age 65 years.

Depression

While depression is an asthma comorbidity, it deserves additional mention due to recent literature showing its negative effects on elderly patients with asthma. Depression is relatively common in adults older than 65 years, affecting up to 20% of older adults in Western countries.⁵⁶ A recent article in the journal demonstrated that older adults with asthma and depression were nearly twice as likely to have poor asthma outcomes across several indicators, including asthma-related emergency department/urgent care visits, compared with those

without depression.⁵⁷ The mechanisms responsible for depression worsening asthma outcomes are not clearly established, and may relate to inflammation, cerebral anatomic changes, autonomic nervous dysfunction, decreased adherence, or ineffective self-management behaviors.⁵⁸

Small trials have shown modest benefit of pharmacotherapy and/or behavioral therapy in the treatment of adults with coexisting asthma and depression, though none were exclusively performed in an older population.^{59–62} Given the prevalence of depression among older adults, its known effects on asthma, and the potential benefit of therapy, asthma providers should consider screening patients for depression (eg, with the Geriatric Depression Scale)⁶³ and treat or refer as appropriate.

Menopause and hormone replacement therapy

Several studies have documented the effects of hormones such as estrogen and progesterone on airway caliber and asthma exacerbations. A study of 2322 perimenopausal women found that the risk of new-onset asthma was 2.4 to 3.4 times higher compared with that in premenopausal women,⁶⁴ and menopause was associated with an accelerated lung function decline.⁶⁵ A separate meta-analysis reported that postmenopausal women on hormone replacement therapy (HRT) had an increased risk of asthma compared with premenopausal women.⁶⁶ Conversely, in

TABLE II. Important nonmedication considerations for older adults with asthma

Item	Possible solution
Symptoms of asthma are often similar to those in other age groups, but differences do exist	Ask about nontraditional asthma symptoms, such as fatigue
Older adults may have a decreased perception of dyspnea	Consider use of a peak flow meter to assist in assessment of airflow obstruction
Bronchial hyperresponsiveness to methacholine increases with age	Interpret results with caution, and consider a higher threshold for an abnormal test result
Older adults with decreased cognition have poor inhaler technique	Consider breath-activated devices, spacers, and nebulizers
Comorbidities are common among older adults, and can negatively impact asthma	Identify, acknowledge, and address comorbidities where appropriate
Depression is especially problematic asthma management for older adults	Consider screening, treatment, and/or referral for depression
Menopause is often associated with asthma exacerbations	The risks and benefits of HRT should be carefully considered in difficult-to-control asthma
Older adults frequently have caregiver roles for their spouse, children, or grandchildren	Acknowledge the challenges, and stress that to be optimally effective you must take care of your own health
Transportation can be problematic	Work with senior service agencies and social workers; schedule multiple appointments on the same day
Frequent use of CAM for asthma	Discuss risks and benefits of such therapies with your patient; consider how breathing exercises and asthma education can be incorporated
Poverty is a growing problem among older adults, and can adversely affect health	Use empathetic communication to discuss financial issues; prescribe medications with the lowest co-pay; refer to appropriate financial services

women with preexisting asthma, HRT may improve respiratory symptoms and decrease exacerbations.⁶⁷

Menopause may also increase the number of asthma exacerbations.^{68,69} There is a spike in exacerbations among women with asthma that occurs at age 50 years,⁷⁰ the mean age of menopause in the United States. This may indicate that sex hormones have a protective effect in asthma, or that fluctuations in hormonal levels can be particularly detrimental. Asthma in women that begins after menopause is frequently severe, non-atopic, and often requires oral corticosteroids for control.^{13,71} The risks and benefits of HRT must be considered, and the asthma care provider is in a unique position to offer specific information to assist in making decisions about HRT.

Caregiver roles and transportation difficulties

Older adults are ever more frequently taking on greater caregiving roles—whether that of a spouse with significant medical problems, a child who is living at home, or a grandchild while the parents work. Being in a stressful caregiver position has been associated with poorer self-reported health, more negative health behaviors, and greater use of health care.⁷² It may be beneficial to inquire and acknowledge the challenges that providing care to others entails, and to highlight that to be optimally effective in such a role requires management of one's own health—including asthma.

Transportation can also be problematic for many older adults. Loss of driving privileges can make follow-up care difficult. The asthma provider can help work with senior service agencies, case managers, or social workers to document the need for follow-up care, and may also try to schedule visits on the same day as other medical appointments.⁷³

Complementary and alternative medicine

The use of complementary and alternative medicine (CAM) to manage asthma symptoms is between 20% and 30%.⁷⁴ An

analysis of more than 7000 adults older than 55 years from the Asthma Call Back Survey found that this number was even higher at 39%.⁷⁵ The most frequent modalities included breathing exercises, vitamins, and herbal therapy. Other research has shown that older adults with asthma rarely, if ever, discuss CAM with their physician.²² Therefore, the provider caring for the older adults with asthma should inquire about CAM usage, discuss potential risks/benefits of such therapies as compared with traditional medicine, and discuss how CAM can be used in conjunction with traditional therapies.

Financial concerns

The current rate among adults older than 65 years living in poverty is approximately 10%, and this number is expected to rise in the upcoming years.⁷⁶ Poverty has numerous detrimental effects on health, such as the inability to afford insurance co-pays, increased exposure to pollution and/or environmental triggers, and increased psychological stress, which worsens asthma. Patients living in poverty often feel ashamed, and few bring up the inability to pay with their provider.⁷⁷ Tangible steps that providers can use include empathetic questions on the ability to afford medications while on a fixed income, prescribing medications with the lowest co-pay, provision of list of financial resources, and referral to social work when appropriate.⁷⁸

PHARMACOLOGIC CHALLENGES/STRATEGIES

Much of the recommendations for asthma management in older patients are based on therapeutic studies mostly in patients primarily younger than 60 years,⁷⁹ and a recent American Thoracic Society workshop report on management of asthma in the elderly specifically noted difficulties in making concrete pharmacologic recommendations.⁸⁰ There are several important challenges, in relationship to both potential age-related responses to therapies and decreases in cognitive and physical functioning. For example, older patients with decreased cognitive function

TABLE III. Medication considerations in older adults with asthma

Medication	Consideration
Short-acting beta agonists	Decline in β -2 receptors density and responsiveness Older adults are more sensitive to adverse effects
Short-acting muscarinic antagonists	May have a more pronounced response than beta agonists as a rescue medication Watch for anticholinergic side effects (ie, falls, urinary symptoms, cognitive impairment)
Inhaled corticosteroids	Preferred controller therapy yet underused Monitor for osteoporosis, cataracts, and glaucoma Less effective than in younger populations
Long-acting beta agonists	Should not be used as monotherapy in asthma Most safety data from COPD trials
Long-acting muscarinic antagonists	Have been shown to be effective as an add-on therapy for older adults More data needed, given older adults' potential preferential bronchodilator response to anticholinergic therapy
Leukotriene receptor antagonists	Show some benefit, but less effective than in younger populations
Specific immunotherapy	Shows benefit in older adults Must consider risks/benefits of anaphylaxis and epinephrine use in patients with cardiac disease
Omalizumab	Show some benefit, but less effective than in younger populations

had poorer inhaler technique.⁸¹ To improve medication delivery and adherence, older patients can be prescribed breath-activated medication devices,⁸² spacers to attach to metered dose inhalers, or medications that can be delivered by nebulizer (including corticosteroids for daily controller use, although this is not currently a Food and Drug Administration indication for patients older than 12 years with asthma), or an Ellipta dry powder inhaler device.⁸³ Furthermore, like treatment of other medical conditions in geriatric medicine, there are issues of polypharmacy, drug-drug interactions, and cost of medications, which can significantly impact optimal treatment. The following sections will address issues of rescue and controller asthma therapies in the aged.

Rescue medications

Although not recently investigated, the literature suggests that older patients may have a more pronounced bronchodilator response to anticholinergic compared with beta₂-agonist therapy.^{84,85} With aging, there may be a decline in beta₂-receptor density, responsiveness, and affinity.^{86,87} Older patients may be more sensitive to adverse effects of beta₂ agonists, particularly those with unstable cardiovascular disorders.^{88,89} Research in adults comparing albuterol to levalbuterol has demonstrated a similar rate of side effects (including headache, tremor, hyperglycemia, and tachycardia), though studies in a predominantly elderly population are lacking.^{90,91} Although more likely with oral agents, cognitive impairment, falls, symptomatic urinary outlet obstruction, and closed angle glaucoma are potential risks of high doses of inhaled anticholinergics.⁹²

Controller therapies

Inhaled corticosteroids (ICSs) are important controller therapies in patients with persistent asthma, yet appear to be underused in older patients.⁹³⁻⁹⁵ There are possible reasons for their underuse in this age group, including concerns for adverse effects of higher doses and underdiagnosis of asthma in older adults. Older patients, in particular women, receiving higher dose ICS (eg, >1000 μ g/d budesonide equivalent) should be monitored closely for decreased bone mineral density and increased fracture risk.⁹⁶⁻⁹⁹ Older patients should be given an ICS with a lower bioavailability and at the lowest dose to control their disease,

with consideration of step-down therapy if he or she is well controlled for at least 3 months. To decrease the effects of corticosteroids on bone resorption, patients should be encouraged to exercise (if possible), avoid excess alcohol intake, and use daily supplemental calcium with vitamin D. Observational studies in the elderly have suggested that ICSs have a small, but significant risk of subcapsular and nuclear cataracts^{100,101} and a small risk for developing glaucoma; however, further studies are needed.¹⁰²

In regard to the effectiveness, data suggest that ICS therapy is less effective in older adults than in younger age groups. T_H17-mediated asthma, marked by neutrophilic inflammation, has been recognized to be less responsive to ICS therapy, and is likely more common among older patients with asthma.¹⁰³ In addition, some older patients with asthma may have a component of fixed airway obstruction.¹⁰⁴ A large, retrospective review of 10 landmark asthma trials in patients with mild-moderate disease on ICS therapy found an age-related increase in treatment failures.¹⁰⁵ In this analysis, the number of patients receiving ICSs was significantly higher than the number receiving all other therapies, suggesting that it may have been underpowered to detect a similarly increased failure with other controller medications.

Despite these findings, ICS use reduces hospital admissions and mortality in older adults,¹⁰⁶ but similar to younger patients with asthma, there are likely specific disease phenotypes that respond better to corticosteroid therapy. The use of ultrafine particle ICS medications may be beneficial in older patients with asthma, who are reported to have more small airway involvement,⁴⁰ but this has not been formally evaluated. Despite these data, ICS therapy is still currently the preferred medication for older patients with persistent disease.

The safety of long-acting beta-agonist use in older patients, particular those with underlying cardiovascular disease, has been most studied in COPD. Studies specifically focused on the safety of this class of drugs in the elderly patients with asthma are lacking; however, the boxed warning for use of long-acting beta agonists as monotherapy applies to all patients with asthma. A recent large Food and Drug Administration—mandated study demonstrated the safety of long-acting beta agonists as add-on therapy in asthma, and included 11% of individuals 64 years or older. While no increased evidence of adverse events was

found in older adults, the study was not adequately powered for that subpopulation.¹⁰⁷ Long-acting muscarinic antagonists have been shown to be efficacious as add-on therapy in patients with asthma up to age 75 years.^{108,109} Their use in older patients with asthma requires further study, particularly if this age group has a preferential bronchodilator response to anticholinergics.

The use of oral controller asthma therapies for older patients is attractive in that it would likely increase compliance due to its ease of use. There are a few studies examining the efficacy of leukotriene receptor antagonists in older patients. Although significant improvement in asthma indices was observed in older patients receiving leukotriene receptor antagonists, it was less pronounced than in younger patients¹¹⁰ and in older patients treated with ICS therapy.^{111,112} The use of methylxanthines (eg, theophylline) in older adults is limited by its relatively weak bronchodilator properties, along with its many side effects and drug interactions.¹¹³

Injectable biologics offer a potentially easier administration and effective medication for older patients with asthma. Most studies of anti-IgE (omalizumab) treatment in older patients with asthma have demonstrated clinical improvement in asthma symptoms and exacerbations, though the response may be less than in younger patients.¹¹⁴⁻¹¹⁷ Analysis of data collected from 2 randomized clinical trials investigating the use of reslizumab (an anti-IL-5 mAb) demonstrates a reduction in asthma exacerbations and improved lung function in patients with LOA.¹¹⁸

NONPHARMACOLOGIC TREATMENTS

A recent review in the journal discussed the current state of nonpharmacologic treatment for severe asthma. While this review was not focused on older adults, it reported that both pulmonary rehabilitation and breathing techniques may be helpful in a subset of patients without causing harm.¹¹⁹ Among older adults, there are limited studies that appear to support these techniques.^{120,121} In addition, older patients with asthma have been shown to have a poorer understanding of their medication use and self-management.¹²² Asthma educational strategies appear beneficial in older adults, although these strategies are frequently underused in this population.^{123,124} For example, a 6-session randomized controlled trial of a self-regulation behavioral intervention demonstrated an improvement in health care utilization, asthma control, and quality of life compared with the control group.¹²⁵

ASTHMA COPD OVERLAP

A specific entity in the differential diagnosis that deserves mention is asthma COPD overlap (ACO), which has also been referred to as asthma COPD overlap syndrome. A recent workshop by the National Institutes of Health and the American Thoracic Society described this disorder as a condition in which patients with asthma have features of COPD, or patients with COPD have features of asthma.¹²⁶ Patients with ACO appear to have more hospitalizations, worse quality of life, and greater symptom burden than do those with asthma or COPD alone.^{127,128} Although precise definition, diagnosis, testing, and treatment options for ACO are still being established, what is most germane to this review is that most patients with ACO will likely be older than 50 years. As the National Institutes of Health workshop participants note, at this time there is not a single, universal definition of ACO for diagnosis and treatment, but

several research themes are emerging. Unquestionably, older adults with asthma will play an important role in future investigations of ACO.¹²⁶

CONCLUSIONS

Asthma among older adults is a common disorder, and as the population of the United States grows older, it will be encountered by anyone who manages adult asthma. As demonstrated in [Tables II and III](#), there are unique features related to diagnosis, medication, and nonpharmaceutical concerns that must be identified and properly managed to provide optimal care. As further research is performed in older adults with asthma, important medical discoveries will ensure that management in the golden years is truly golden.

REFERENCES

- Mather M, Jacobsen LA, Pollard KM. Aging in the United States. *Population Bull* 2015;70:1-17.
- Bellia V, Battaglia S, Catalano F, Scichilone N, Incalzi RA, Imperiale C, et al. Aging and disability affect misdiagnosis of COPD in elderly asthmatics: the SARA study. *Chest* 2003;123:1066-72.
- Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. *J Asthma* 2006;43:75-80.
- Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. *JAMA* 2000;283:1853-7.
- U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Health Interview Survey, 2015. Table A-2. Available from: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2015_SHS_Table_A-2.pdf. Accessed January 5, 2018.
- Winer RA, Qin X, Harrington T, Moorman J, Zahran H. Asthma incidence among children and adults: findings from the Behavioral Risk Factor Surveillance system asthma call-back survey—United States, 2006-2008. *J Asthma* 2012;49:16-22.
- Baptist AP, Hao W, Karamched KR, Kaur B, Carpenter L, Song PXX. Distinct asthma phenotypes among older adults with asthma. *J Allergy Clin Immunol Pract* 2018;6:244-249.e2.
- de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? *Eur Respir Rev* 2013;22:44-52.
- Baptist AP, Ross JA, Clark NM. Older adults with asthma: does age of asthma onset make a difference? *J Asthma* 2013;50:836-41.
- Herscher ML, Wisnivesky JP, Busse PJ, Hanania NA, Sheng T, Wolf MS, et al. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. *J Asthma* 2017;54:223-9.
- Park HW, Song WJ, Kim SH, Park HK, Kim SH, Kwon YE, et al. Classification and implementation of asthma phenotypes in elderly patients. *Ann Allergy Asthma Immunol* 2015;114:18-22.
- Kochanek KD, Murphy SL, Xu JQ, Tejada-Vera B. Deaths: final data for 2014. *Natl Vital Stat Rep* 2016;65:1-122.
- Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 2010;181:315-23.
- Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. *Eur Respir J* 2015;46:1308-21.
- Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2014 Emergency Department Summary Tables. Available from: http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2014_ed_web_tables.pdf. Accessed January 5, 2018.
- Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci* 2014;69:S4-9.
- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell* 2013;153:1194-217.
- Bauer BA, Reed CE, Yunginger JW, Wollan PC, Silverstein MD. Incidence and outcomes of asthma in the elderly: a population-based study in Rochester, Minnesota. *Chest* 1997;111:303-10.

19. Nyenhuis SM, Schwantes EA, Evans MD, Mathur SK. Airway neutrophil inflammatory phenotype in older subjects with asthma. *J Allergy Clin Immunol* 2010;125:1163-5.
20. Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. *Chest* 2012;142:86-93.
21. Busse PJ, Birmingham JM, Calatroni A, Manzi J, Goryachokovsky A, Fontela G, et al. Effect of aging on sputum inflammation and asthma control. *J Allergy Clin Immunol* 2017;139:1808-1818.e6.
22. Baptist AP, Deol BB, Reddy RC, Nelson B, Clark NM. Age-specific factors influencing asthma management by older adults. *Qual Health Res* 2010;20:117-24.
23. Quadrelli SA, Roncoroni A. Features of asthma in the elderly. *J Asthma* 2001;38:377-89.
24. Weiner P, Magadle R, Waizman J, Weiner M, Rabner M, Zamir D. Characteristics of asthma in the elderly. *Eur Respir J* 1998;12:564-8.
25. Raiha I, Impivaara O, Seppala M, Knuts LR, Sourander L. Determinants of symptoms suggestive of gastroesophageal reflux disease in the elderly. *Scand J Gastroenterol* 1993;28:1011-4.
26. Vaz Frago CA, McAvay G, Van Ness PH, Casaburi R, Jensen RL, MacIntyre N, et al. Phenotype of normal spirometry in an aging population. *Am J Respir Crit Care Med* 2015;192:817-25.
27. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40:1324-43.
28. Renwick DS, Connolly MJ. The relationship between age and bronchial responsiveness: evidence from a population survey. *Chest* 1999;115:660-5.
29. Cuttitta G, Cibella F, Bellia V, Grassi V, Cossi S, Buccheri S, et al. Changes in FVC during methacholine-induced bronchoconstriction in elderly patients with asthma: bronchial hyperresponsiveness and aging. *Chest* 2001;119:1685-90.
30. Scichilone N, Messina M, Battaglia S, Catalano F, Bellia V. Airway hyperresponsiveness in the elderly: prevalence and clinical implications. *Eur Respir J* 2005;25:364-75.
31. Bellia V, Battaglia S, Matera MG, Cazzola M. The use of bronchodilators in the treatment of airway obstruction in elderly patients. *Pulm Pharmacol Ther* 2006;19:311-9.
32. Luoto JA, Elmstahl S, Wollmer P, Pihlgard M. Incidence of airflow limitation in subjects 65-100 years of age. *Eur Respir J* 2016;47:461-72.
33. Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. *Postgrad Med J* 2002;78:37-9.
34. Allen SC, Yeung P. Inability to draw intersecting pentagons as a predictor of unsatisfactory spirometry technique in elderly hospital inpatients. *Age Ageing* 2006;35:304-6.
35. Bellia V, Pistelli R, Catalano F, Antonelli-Incalzi R, Grassi V, Melillo G, et al. Quality control of spirometry in the elderly. The S.A.R.A. study. *SAIute Respirazione nell'Anziano = Respiratory Health in the Elderly*. *Am J Respir Crit Care Med* 2000;161:1094-100.
36. Bellia V, Pistelli R, Catalano F, Antonelli-Incalzi R, Grassi V, Melillo G, et al. Quality control of spirometry in the elderly. *Am J Respir Crit Care Med* 2000;161:1094-100.
37. Sherman CB, Kern D, Richardson ER, Hubert M, Fogel BS. Cognitive function and spirometry performance in the elderly. *Am Rev Respir Dis* 1993;148:123-6.
38. Enright PL, McClelland RL, Buist AS, Lebowitz MD. Correlates of peak expiratory flow variability in elderly persons. *Chest* 2001;120:1861-8.
39. Enright PL, Burchette RJ, Peters JA, Lebowitz MD, McDonnell WF, Abbey DE. Peak flow variability: association with asthma and spirometry in an older cohort. *Chest* 1997;112:895-901.
40. Inoue H, Niimi A, Takeda T, Matsumoto H, Ito I, Matsuoka H, et al. Pathophysiological characteristics of asthma in the elderly: a comprehensive study. *Ann Allergy Asthma Immunol* 2014;113:527-33.
41. Toren K, Murgia N, Schioler L, Bake B, Olin AC. Reference values of fractional excretion of exhaled nitric oxide among non-smokers and current smokers. *BMC Pulm Med* 2017;17:118.
42. Malerba M, Damiani G, Carpagnano GE, Olivini A, Radaeli A, Ragnoli B, et al. Values in elderly people for exhaled nitric oxide study. *Rejuv Res* 2016;19:233-8.
43. Bozek A, Filipowski M, Fischer A, Jarzab J. Characteristics of atopic bronchial asthma in seniors over 80 years of age. *Biomed Res Int* 2013;2013:689782.
44. Porsbjerg CM, Gibson PG, Pretto JJ, Salome CM, Brown NJ, Berend N, et al. Relationship between airway pathophysiology and airway inflammation in older asthmatics. *Respirology* 2013;18:1128-34.
45. Langley SJ, Goldthorpe S, Craven M, Morris J, Woodcock A, Custovic A. Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. *J Allergy Clin Immunol* 2003;112:362-8.
46. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. *Am J Respir Crit Care Med* 2010;181:1033-41.
47. Godinho Netto AC, Dos Reis TG, Matheus CF, Aarestrup BJ, Aarestrup FM. Fraction of exhaled nitric oxide measurements in the diagnoses of asthma in elderly patients. *Clin Interv Aging* 2016;11:623-9.
48. Kawamatawong T, Siripongpun S, Rerkpattanapipat T. Role of eosinophilic inflammation and atopy in elderly asthmatic patients. *Asia Pacific Allergy* 2016;6:181-6.
49. Su X, Ren Y, Li M, Zhao X, Kong L, Kang J. Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis. *Medicine (Baltimore)* 2016;95:e3459.
50. Patel MR, Janevic MR, Heeringa SG, Baptist AP, Clark NM. An examination of adverse asthma outcomes in U.S. adults with multiple morbidities. *Ann Am Thorac Soc* 2013;10:426-31.
51. Hsu J, Chen J, Mirabelli MC. Asthma morbidity, comorbidities, and modifiable factors among older adults. *J Allergy Clin Immunol Pract* 2018;6:236-243.e7.
52. Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS. Descriptions of barriers to self-care by persons with comorbid chronic diseases. *Ann Fam Med* 2003;1:15-21.
53. Tay TR, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R, et al. A structured approach to specialist-referred difficult asthma patients improves control of comorbidities and enhances asthma outcomes. *J Allergy Clin Immunol Pract* 2017;5:956-964.e3.
54. Oka A, Hirano T, Yamaji Y, Ito K, Oishi K, Edakuni N, et al. Determinants of incomplete asthma control in patients with allergic rhinitis and asthma. *J Allergy Clin Immunol Pract* 2017;5:160-4.
55. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. *Int Arch Allergy Immunol* 2004;135:332-5.
56. Volkert J, Schulz H, Harter M, Wlodarczyk O, Andreas S. The prevalence of mental disorders in older people in Western countries—a meta-analysis. *Ageing Res Rev* 2013;12:339-53.
57. Patel PO, Patel MR, Baptist AP. Depression and asthma outcomes in older adults: results from the National Health and Nutrition Examination Survey. *J Allergy Clin Immunol Pract* 2017;5:1691-1697.e1.
58. Wang L, Wang T, Liu S, Liang X, Meng Y, Xiong X, et al. Cerebral anatomical changes in female asthma patients with and without depression compared to healthy controls and patients with depression. *J Asthma* 2014;51:927-33.
59. Brown ES, Vornik LA, Khan DA, Rush AJ. Bupropion in the treatment of outpatients with asthma and major depressive disorder. *Int J Psychiatry Med* 2007;37:23-8.
60. Mancuso CA, Sayles W, Allegrante JP. Randomized trial of self-management education in asthmatic patients and effects of depressive symptoms. *Ann Allergy Asthma Immunol* 2010;105:12-9.
61. Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. *Psychosomatics* 2012;53:75-80.
62. Yorke J, Adair P, Doyle AM, Dubrow-Marshall L, Fleming S, Holmes L, et al. A randomised controlled feasibility trial of group cognitive behavioural therapy for people with severe asthma. *J Asthma* 2017;54:543-54.
63. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res* 1982;17:37-49.
64. Triebner K, Johannessen A, Puggini L, Benediktsdottir B, Bertelsen RJ, Bifulco E, et al. Menopause as a predictor of new-onset asthma: a longitudinal Northern European population study. *J Allergy Clin Immunol* 2016;137:50-57.e56.
65. Triebner K, Matulonga B, Johannessen A, Suske S, Benediktsdottir B, Demoly P, et al. Menopause is associated with accelerated lung function decline. *Am J Respir Crit Care Med* 2017;195:1058-65.
66. Zemp E, Schikowski T, Dratva J, Schindler C, Probst-Hensch N. Asthma and the menopause: a systematic review and meta-analysis. *Maturitas* 2012;73:212-7.
67. Kos-Kudla B, Ostrowska Z, Marek B, Ciesielska-Kopacz N, Kajdaniuk D, Kudla M. Effects of hormone replacement therapy on endocrine and

- spirometric parameters in asthmatic postmenopausal women. *Gynecol Endocrinol* 2001;15:304-11.
68. Balzano G, Fuschillo S, Melillo G, Bonini S. Asthma and sex hormones. *Allergy* 2001;56:13-20.
 69. Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. *Endocr Rev* 2012;33:1-47.
 70. Skobeloff EM, Spivey WH, St Clair SS, Schoffstall JM. The influence of age and sex on asthma admissions. *JAMA* 1992;268:3437-40.
 71. Balzano G, Fuschillo S, De Angelis E, Gaudiosi C, Mancini A, Caputi M. Persistent airway inflammation and high exacerbation rate in asthma that starts at menopause. *Monaldi Arch Chest Dis* 2007;67:135-41.
 72. Son J, Erno A, Shea DG, Femia EE, Zarit SH, Stephens MA. The caregiver stress process and health outcomes. *J Aging Health* 2007;19:871-87.
 73. Dugdale DC, Epstein R, Pantilat SZ. Time and the patient-physician relationship. *J Gen Intern Med* 1999;14:S34-40.
 74. Slader CA, Reddel HK, Jenkins CR, Armour CL, Bosnic-Anticevich SZ. Complementary and alternative medicine use in asthma: who is using what? *Respirology* 2006;11:373-87.
 75. Ward CE, Baptist AP. Characteristics of complementary and alternative medicine (CAM) use among older adults with asthma. *J Asthma* 2016;53:546-52.
 76. National Council on Aging. Economic security for seniors facts. Available from: <https://www.ncoa.org/news/resources-for-reporters/get-the-facts/economic-security-facts/>. Accessed January 18, 2017.
 77. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. *JAMA* 2003;290:953-8.
 78. Hardee JT, Platt FW, Kasper IK. Discussing health care costs with patients: an opportunity for empathic communication. *J Gen Intern Med* 2005;20:666-9.
 79. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J Allergy Clin Immunol* 2007;120:S94-138.
 80. Skloot GS, Busse PJ, Braman SS, Kovacs EJ, Dixon AE, Vaz Fragoso CA, et al. An official American Thoracic Society workshop report: evaluation and management of asthma in the elderly. *Ann Am Thorac Soc* 2016;13:2064-77.
 81. Allen SC, Jain M, Ragab S, Malik N. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. *Age Ageing* 2003;32:299-302.
 82. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. *Chest* 1993;104:1332-7.
 83. Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Abo M, et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in elderly asthmatics. *Drug Res (Stuttg)* 2018;68:38-44.
 84. van Schayck CP, Folgering H, Harbers H, Maas KL, van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. *Thorax* 1991;46:355-9.
 85. Barros MJ, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. *Respir Med* 1990;84:371-5.
 86. Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. *Pharmacol Ther* 1993;60:389-404.
 87. Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Impaired bronchodilator response to albuterol in healthy elderly men and women. *Chest* 1995;108:401-6.
 88. Bellia V, Pedone C, Catalano F, Zito A, Davi E, Palange S, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. *Chest* 2007;132:1175-82.
 89. Gupta P, O'Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. *Drugs Aging* 2008;25:415-43.
 90. Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K, et al. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. *Clin Ther* 2008;30:989-1002.
 91. Nowak R, Emerman C, Hanrahan JP, Parsey MV, Hanania NA, Claus R, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. *Am J Emerg Med* 2006;24:259-67.
 92. Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. *Aging Clin Exp Res* 2016;28:25-35.
 93. Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. *Cardiovascular Health Study Research Group*. *Chest* 1999;116:603-13.
 94. Hartert TV, Togias A, Mellen BG, Mitchel EF, Snowden MS, Griffin MR. Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. *J Am Geriatr Soc* 2000;48:651-7.
 95. Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. *Chest* 2001;119:720-5.
 96. Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. *Drug Saf* 2008;31:409-14.
 97. Battaglia S, Cardillo I, Lavorini F, Spatafora M, Scichilone N. Safety considerations of inhaled corticosteroids in the elderly. *Drugs Aging* 2014;31:787-96.
 98. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. *Am J Respir Crit Care Med* 2004;169:83-8.
 99. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. *Ann Allergy Asthma Immunol* 2005;94:15-21. quiz 22-13, 79.
 100. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. *JAMA* 1998;280:539-43.
 101. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. *Eur Respir J* 2006;27:1168-74.
 102. Leone FT, Fish JE, Szeffer SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. *Chest* 2003;124:2329-40.
 103. Busse PJ, Birmingham JM, Calatroni A, Manzi J, Goryachovsky A, Fontela G, et al. The effect of aging on sputum inflammation and asthma control. *J Allergy Clin Immunol* 2017;139:1808-1818.e6.
 104. Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly: a comparison between patients with recently acquired and long-standing disease. *Am Rev Respir Dis* 1991;143:336-40.
 105. Dunn RM, Lehman E, Chinchilli VM, Martin RJ, Boushey HA, Israel E, et al. Impact of age and gender on response to asthma therapy. *Am J Respir Crit Care Med* 2015;192:551-8.
 106. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. *Eur Respir J* 2001;17:380-5.
 107. Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. *N Engl J Med* 2016;374:1822-30.
 108. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med* 2012;367:1198-207.
 109. Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomized trials. *Lancet Respir Med* 2015;3:367-76.
 110. Korenblat PE, Kemp JP, Scherger JE, Minkwitz MC, Mezzanotte W. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoeconomics Trial (ACCEPT). *Ann Allergy Asthma Immunol* 2000;84:217-25.
 111. Creticos P, Knobil K, Edwards LD, Rickard KA, Dorinsky P. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. *Ann Allergy Asthma Immunol* 2002;88:401-9.
 112. Bozek A, Warkocka-Szolysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. *J Asthma* 2012;49:530-4.
 113. Shannon M, Lovejoy FH Jr. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. *Arch Intern Med* 1990;150:2045-8.
 114. Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. *J Asthma* 2008;45:173-81.
 115. Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. *Ann Allergy Asthma Immunol* 2010;105:313-9.
 116. Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, et al. Effects of omalizumab in severe asthmatics across ages: a real life Italian experience. *Respir Med* 2016;119:141-9.
 117. Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. *Ann Allergy Asthma Immunol* 2016;117:546-9.

118. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. *Pulmon Pharmacol Therapeut* 2017;43:39-45.
119. Hall C, Nici L, Sood S, ZuWallack R, Castro M. Nonpharmacologic therapy for severe persistent asthma. *J Allergy Clin Immunol Pract* 2017;5:928-35.
120. Gomieiro LT, Nascimento A, Tanno LK, Agondi R, Kalil J, Giavina-Bianchi P. Respiratory exercise program for elderly individuals with asthma. *Clinics (Sao Paulo)* 2011;66:1163-9.
121. Majewski M, Dabrowska G, Pawik M, Rozek K. Evaluation of a home-based pulmonary rehabilitation program for older females suffering from bronchial asthma. *Adv Clin Exp Med* 2015;24:1079-83.
122. Soones TN, Lin JL, Wolf MS, O'Connor R, Martynenko M, Wisnivesky JP, et al. Pathways linking health literacy, health beliefs, and cognition to medication adherence in older adults with asthma. *J Allergy Clin Immunol* 2017; 139:804-9.
123. O'Connor R, Martynenko M, Gagnon M, Hauser D, Young E, Lurio J, et al. A qualitative investigation of the impact of asthma and self-management strategies among older adults. *J Asthma* 2017;54:39-45.
124. Goeman D, Jenkins C, Crane M, Paul E, Douglass J. Educational intervention for older people with asthma: a randomised controlled trial. *Patient Educ Couns* 2013;93:586-95.
125. Baptist AP, Ross JA, Yang Y, Song PX, Clark NM. A randomized controlled trial of a self-regulation intervention for older adults with asthma. *J Am Geriatr Soc* 2013;61:747-53.
126. Woodruff PG, van den Berge M, Boucher RC, Brightling C, Burchard EG, Christensen SA, et al. American Thoracic Society/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report. *Am J Respir Crit Care Med* 2017;196:375-81.
127. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, et al. Overlap syndrome of asthma and COPD predicts low quality of life. *J Asthma* 2011;48:279-85.
128. de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. *PLoS One* 2013;8:e62985.
129. Meyer KC, Soergel P. Variation of bronchoalveolar lymphocyte phenotypes with age in the physiologically normal human lung. *Thorax* 1999;54:697-700.
130. Ducharme ME, Prince P, Hassan N, Nair P, Boulet LP. Expiratory flows and airway inflammation in elderly asthmatic patients. *Respir Med* 2011;105: 1284-9.
131. Sapay E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. *Blood* 2014;123:239-48.
132. Tseng CW, Kyme PA, Arruda A, Ramanujan VK, Tawackoli W, Liu GY. Innate immune dysfunctions in aged mice facilitate the systemic dissemination of methicillin-resistant *S. aureus*. *PLoS One* 2012;7:e41454.
133. Fortin CF, Larbi A, Lesur O, Douziech N, Fulop T Jr. Impairment of SHP-1 down-regulation in the lipid rafts of human neutrophils under GM-CSF stimulation contributes to their age-related, altered functions. *J Leukoc Biol* 2006;79:1061-72.
134. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. *J Leukoc Biol* 2004;76:291-9.
135. Verschoor CP, Loukov D, Naidoo A, Puchta A, Johnstone J, Millar J, et al. Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. *Mol Immunol* 2015;65:148-56.
136. Baptista G, Dupuy AM, Jaussent A, durant R, Ventura E, Sauguet P, et al. Low-grade chronic inflammation and superoxide anion production by NADPH oxidase are the main determinants of physical frailty in older adults. *Free Radic Res* 2012;46:1108-14.
137. Ogawa K, Suzuki K, Okutsu M, Yamazaki K, Shinkai S. The association of elevated reactive oxygen species levels from neutrophils with low-grade inflammation in the elderly. *Immun Ageing* 2008;5:13.
138. Mathur SK, Schwantes EA, Jarjour NN, Busse WW. Age-related changes in eosinophil function in human subjects. *Chest* 2008;133:412-9.
139. Annema JT, Sparrow D, O'Connor GT, Rijcken B, Koëter GH, Postma DS, et al. Chronic respiratory symptoms and airway responsiveness to methacholine are associated with eosinophilia in older men: the Normative Aging Study. *Eur Respir J* 1995;8:62-9.
140. Agrawal A, Tay J, Ton S, Agrawal S, Gupta S. Increased reactivity of dendritic cells from aged subjects to self-antigen, the human DNA. *J Immunol* 2009; 182:1138-45.
141. Canaday DH, Amponsah NA, Jones L, Tisch DJ, Hornick TR, Ramachandra L. Influenza-induced production of interferon-alpha is defective in geriatric individuals. *J Clin Immunol* 2010;30:373-83.
142. Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. *J Immunol* 2007;178:6912-22.
143. Panda A, Qian F, Mohanty S, van Duin D, Newman FK, Zhang L, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. *J Immunol* 2010;184:2518-27.
144. Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. *J Clin Invest* 2011;121:4921-30.
145. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. *Aging Cell* 2004;3:161-7.
146. van Duin D, Mohanty S, Thomas V, Giner S, Montgomery RR, Fikrig E, et al. Age-associated defect in human TLR-1/2 function. *J Immunol* 2007;178:970-5.
147. Oishi Y, Manabe I. Macrophages in age-related chronic inflammatory diseases. *NPJ Aging Mech Dis* 2016;2:16018.
148. Ho JC, Chan KN, Hu WH, Lam WK, Zheng L, Tipoe GL, et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. *Am J Respir Crit Care Med* 2001;163:983-8.
149. Svartengren M, Falk R, Philipson K. Long-term clearance from small airways decreases with age. *Eur Respir J* 2005;26:609-15.
150. Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier: structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. *J Clin Invest* 1995;95:2281-90.
151. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *Lancet* 2005;366:1165-74.
152. Kogut I, Scholz JL, Cancro MP, Cambier JC. B cell maintenance and function in aging. *Semin Immunol* 2012;24:342-9.
153. Barbee RA, Halonen M, Lebowitz M, Burrows B. Distribution of IgE in a community population sample: correlations with age, sex, and allergen skin test reactivity. *J Allergy Clin Immunol* 1981;68:106-11.
154. Sapigni T, Biavati P, Simoni M, Viegi G, Baldacci S, Carrozzi L, et al. The Po River Delta Respiratory Epidemiological Survey: an analysis of factors related to level of total serum IgE. *Eur Respir J* 1998;11:278-83.
155. Jarvis D, Luczynska C, Chinn S, Potts J, Sunyer J, Janson C, et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. *J Allergy Clin Immunol* 2005;116:675-82.
156. Kerkhof M, Droste JH, de Monchy JG, Schouten JP, Rijcken B. Distribution of total serum IgE and specific IgE to common aeroallergens by sex and age, and their relationship to each other in a random sample of the Dutch general population aged 20-70 years. Dutch ECRHS Group, European Community Respiratory Health Study. *Allergy* 1996;51:770-6.
157. Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. *Semin Respir Crit Care Med* 2010;31: 561-74.
158. Tsukamoto H, Clise-Dwyer K, Huston GE, Duso DK, Buck AL, Johnson LL, et al. Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. *Proc Natl Acad Sci U S A* 2009;106:18333-8.
159. Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, et al. The influence of age on T cell generation and TCR diversity. *J Immunol* 2005;174:7446-52.
160. Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. *J Immunol* 2014;192: 2689-98.
161. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. *J Immunol* 2002;169:1984-92.
162. Heron M, Grutters JC, ten Dam-Molenkamp KM, Hijdra D, van Heugten-Roeling A, Claessen AM, et al. Bronchoalveolar lavage cell pattern from healthy human lung. *Clin Exp Immunol* 2012;167:523-31.
163. Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. *Exp Gerontol* 2013;48:1379-86.
164. Birmingham JM, Gillespie VL, Srivastava K, Li XM, Busse PJ. Influenza A infection enhances antigen-induced airway inflammation and hyper-responsiveness in young but not aged mice. *Clin Exp Allergy* 2014;44: 1188-99.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.